Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Scott D. Solomon et al.|New England Journal of Medicine|2019Cited by 6.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren Lund Kristensen, John J.V. McMurray, Rasmus Rørth et al.|The Lancet Diabetes & Endocrinology|2019Cited by 1.6k
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, John J.V. McMurray et al.|New England Journal of Medicine|2024Cited by 693
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trialsMuthiah Vaduganathan, Scott D. Solomon, Brian Claggett et al.|The Lancet|2020Cited by 645
Declining Risk of Sudden Death in Heart FailureLi Shen, John J.V. McMurray, Pardeep S. Jhund et al.|New England Journal of Medicine|2017Cited by 500